Thrombin inhibitor

Thrombin inhibitor

Thrombin inhibitors are one type of anticoagulant medication, used to help prevent formation of harmful blood clots in the body by blocking the activity of thrombin.
References in periodicals archive ?
Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention.
Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.
Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention, a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.
The direct thrombin inhibitor dabigatran (Pradaxa) is contraindicated in chronic renal failure.
cleverly showed that a direct thrombin inhibitor could reduce the progression of atherosclerosis in apolipoprotein E-deficient mice through the inhibition of the transcription of multiple proinflammatory factors [9].
The HemosIL Rivaroxaban Testing Solution is the second assay IL has commercialised in the company's DOAC Assay Panel, following the introduction of their HemosIL Direct Thrombin Inhibitor Assay for measurement of dabigatran (Pradaxa) in September 2014.
Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) and heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing PCI, concluded the company.
The development of new factor Xa and direct thrombin inhibitor drugs have made the logistics of providing adequate thrombus prevention much simpler, if somewhat more expensive.
1] The first novel anticoagulant (NOAC) and direct thrombin inhibitor (DTI), lepirudin, originates from 1998, when its intravenous form was approved for the use of clinically relevant heparin-induced thrombocytopenia (HIT).
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.